MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry (Q38044236)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 September 2012

Language	Label	Description	Also known as
English	MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry	scientific article published on 18 September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry (English)

1 reference

Europe PubMed Central

27 August 2017

immunohistochemistry

1 reference

based on heuristic

inferred from title

author name string

Sofia Mason

1

1 reference

Europe PubMed Central

27 August 2017

Kerrie McDonald

2

1 reference

Europe PubMed Central

27 August 2017

publication date

18 September 2012

1 reference

Europe PubMed Central

27 August 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

27 August 2017

138

1 reference

Europe PubMed Central

27 August 2017

1789-1797

1 reference

Europe PubMed Central

27 August 2017

11

1 reference

Europe PubMed Central

27 August 2017

https://scigraph.springernature.com/pub.10.1007/s00432-012-1312-1

0 references

Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: An immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

MGMT hypermethylation: a prognostic foe, a predictive friend

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

MGMT promoter methylation in malignant gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Long-term survivors of glioblastoma: clinical features and molecular analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Optimal role of temozolomide in the treatment of malignant gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1312-1

21 January 2018

Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The evolution of personalized cancer genetic counseling in the era of personalized medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MGMT immunohistochemical expression and promoter methylation in human glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MGMT promoter hypermethylation in a series of 104 glioblastomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22986811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-012-1312-1

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38044236&oldid=1738343356"